23.12
-0.24 (-1.03%)
| Previous Close | 23.36 |
| Open | 22.98 |
| Volume | 357,858 |
| Avg. Volume (3M) | 657,019 |
| Market Cap | 1,701,029,632 |
| Price / Earnings (Forward) | 24.69 |
| Price / Sales | 22.85 |
| Price / Book | 11.10 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Profit Margin | -121.73% |
| Operating Margin (TTM) | -94.48% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | 170.30% |
| Total Debt/Equity (MRQ) | 5.68% |
| Current Ratio (MRQ) | 4.71 |
| Operating Cash Flow (TTM) | -75.78 M |
| Levered Free Cash Flow (TTM) | -21.20 M |
| Return on Assets (TTM) | -13.89% |
| Return on Equity (TTM) | -29.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Zymeworks Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -3.5 |
| Average | -1.50 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 102.76% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capricorn Fund Managers Ltd | 31 Mar 2026 | 1,007,210 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |